A study looking at nanoparticles and heat to destroy prostate cancer (MAGNABLATE I Trial)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Bladder cancer
Prostate cancer




Phase 0

This study is looking at a new way of treating prostate cancer called magnetic nanoparticle thermablation. This means using magnetism to heat up tiny particles placed in the prostate gland.

One way of treating prostate cancer is to have surgery to remove the prostate gland. This works well but there are unpleasant long term side effects. So doctors are always looking for ways to improve treatment.

Magnetic nanoparticle thermablation is a very new way of possibly treating prostate cancer. Nanoparticles are very tiny pieces of iron that are injected into the prostate gland. A magnetic field heats up these nanoparticles. This will kill all the tissue containing the nanoparticles.

As this is a new treatment, the researchers need to know that the nanoparticles will stay in the prostate gland. This is what they want to find out in this study.

To do this, they will ask men having surgery to remove their prostate to take part in this study. Before your prostate is removed the researchers will inject it with nanoparticles. After your prostate is removed they will look at it to see if the nanoparticles have stayed where they were injected.

The researchers won’t heat the nanoparticles as part of this study. And taking part won’t affect your treatment in any way.

Who can enter

You may be able to join this study if you have prostate cancer or bladder cancer and are having surgery to remove your prostate gland Open a glossary item.

You cannot join this study if any of these apply. You

  • Have had hormone therapy Open a glossary item in the past 6 months
  • Aren’t able to have a general anaesthetic Open a glossary item
  • Are not able to have an MRI scan because you have certain types of metal surgical clips or plates in your body, or a pacemaker
  • Are not able to have a CT scan
  • Have a medical condition, or are on medication, that affects your immune system
  • Have a bleeding problem
  • Have a problem with blood clots
  • Have a condition that affects the way your body deals with iron (your doctor can tell you this)

Trial design

The researchers need 18 men to join this study.

You have a general anaesthetic Open a glossary item as usual. When you are asleep, the researchers will use a needle to inject the nanoparticles into your prostate gland. This will take about 15 minutes.

When they have done this, your surgery will go ahead as your surgeon has told you. The nanoparticles won’t affect your surgery in any way.

The researchers will then look at tissue samples of your prostate to see if the nanoparticles have stayed where they were injected.

Hospital visits

There are no extra visits if you take part in this study.

Side effects

Apart from slight bruising and small amount of bleeding at the injection sites, the researchers don’t expect any side effects from taking part in this study.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Mr Hashim Uddin Ahmed

Supported by

NIHR Central Commissioning Facility
NIHR Clinical Research Network: Cancer
University College Hospital

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 11781

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page